This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent Down on '18 View, Posts Preliminary '17 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.
Merck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study
by Zacks Equity Research
Merck (MRK) announced that a phase III study evaluating Keytruda as monotherapy for the treatment of high-risk melanoma met the primary endpoint.
4 Biotech Stocks to Watch in the New Year
by Zacks Equity Research
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
Will J&J (JNJ) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.
Novartis Gets Second Breakthrough Designation for Kisqali
by Zacks Equity Research
Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
5 Reasons to Pick Emergent as an Investment-Worthy Stock
by Zacks Equity Research
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now
by Zacks Equity Research
Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.
Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31
by Zacks Equity Research
Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.
Glaxo's Nucala Label Expansion Application Gets FDA Approval
by Zacks Equity Research
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
by Zacks Equity Research
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
3 Drug/Biotech Stocks in Focus on World AIDS Day
by Zacks Equity Research
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Gilead & 3 Other Drug Stocks in Focus this World AIDS Day
by Arpita Dutt
With 36.7 million people living with HIV, there remains significant need for new and improved drugs in this corner of the market that has players like Gilead (GILD).
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
Glaxo Stock Down So Far This Year: Is a Reversal in Store?
by Zacks Equity Research
Glaxo's shares have declined 7.9% this year so far.
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA
by Zacks Equity Research
Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
by Zacks Equity Research
Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
by Zacks Equity Research
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3
by Zacks Equity Research
Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.